TSLP Peptide

  • Check with publisher
  • Published date: December 21, 2018
    • Shirley, New York, United States

This gene encodes a hemopoietic cytokine proposed to signal through a heterodimeric receptor complex composed of the thymic stromal lymphopoietin receptor and the IL-7R alpha chain. It mainly impacts myeloid cells and induces the release of T cell-attracting chemokines from monocytes and enhances the maturation of CD11c(+) dendritic cells. The protein promotes T helper type 2 (TH2) cell responses that are associated with immunity in various inflammatory diseases, including asthma, allergic inflammation and chronic obstructive pulmonary disease. The protein is therefore considered a potential therapeutic target for the treatment of such diseases. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Jan 2012]. https://www.creative-diagnostics.com/TSLP-Peptide-180214-436.htm .

Result 0 votes
Thomas Schmitt
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Human TRIM71 blocking peptide

    Human TRIM71 blocking peptide

    Molecular Biology Shirley (New York) December 21, 2018 Check with publisher

    TRIM71 (tripartite motif containing 71, E3 ubiquitin protein ligase) is a protein-coding gene. Diseases associated with TRIM71 include otitis media, and cholesteatoma. GO annotations related to this gene include ubiquitin-protein ligase activity and ...

  • Epstein-Barr Virus Vaccines

    Epstein-Barr Virus Vaccines

    Molecular Biology Shirley (New York) November 30, 2018 Check with publisher

    EBV vaccines to prevent primary infection or disease, or therapeutic vaccines to treat EBV malignancies have not been licensed. Most efforts to develop prophylactic vaccines have focused on EBV gp350, which is the major target of neutralizing antibod...

  • Design and Modification of Allogeneic Cell Vaccines

    Design and Modification of Allogeneic Cell Vaccines

    Molecular Biology Shirley (New York) November 30, 2018 Check with publisher

    Tumor cells are generally thought to be poorly immunogenic, although immunogenicity varies considerably between tumors of different backgrounds. Creative Biolabs is a world leader in the field of cancer vaccine development. We have a variety of strat...